RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia

Haemophilia

Volumn 13, Issue 4, 2007, Pages 345-350

  Fischer, K ^a,b   Grobbee, D E ^b   van den Berg, H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bleeds; Observational studies; Prophylaxis; Randomized controlled trial; Study design

Indexed keywords

BLOOD CLOTTING FACTOR;

ARTHROPATHY; ARTICLE; BLEEDING; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FOLLOW UP; HEMOPHILIA; HUMAN; INTERNAL VALIDITY; LONG TERM CARE; LOW DRUG DOSE; METHODOLOGY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SOCIOECONOMICS;

HEMOPHILIA A; HUMANS; OBSERVATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 34447252105     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01521.x     Document Type: Article

References (34)

1. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with haemophilia A or B (review). Cochrane Database Syst Rev 2005; 2: CD003429. doi: 10.1002/14651858.CD003429.pub2.
2. Manco Johnson MJ, Abshire T, Brown D et al. Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency. Blood 2005; 106: 6a (Abstract 3).
3. Aledort L, Ljung R, Blanchette V. Are randomized clinical trials the only truth? Not always. J Thromb Haemost 2006; 4: 503-4.
4. Mannucci PM. Need for randomized trials in hemophilia. J Thromb Haemost 2006; 4: 501-2.
5. The medical and scientific advisory council of the national haemophilia foundation. More on: Are randomized clinical trials the only truth? Not always. J Thromb Haemost 2006; 4: 1167-8.
6. White GC. Parachutes and prophylaxis: They both work! J Thromb Haemost 2006; 4: 1226-7.
7. Gringeri A, ESPRIT Study Group Evaluation Study on Prophylaxis: A randomised Italian Trial (Esprit). Two-years report. Thromb Haemost 1999; 82: S470.(Abstract 1487).
8. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ 1997; 315: 1151-4.
9. Mamdani M, Sykora K, Li P et al. Reader's guide to critical appraisal of cohort studies: 2. assessing potential for confounding. BMJ 2005; 330: 960-2.
10. Hak E, Verheij TJ, Grobbee DE, Nichol KL, Hoes AW. Confounding by indication in non-experimental evaluation of vaccine effectiveness: The example of prevention of influenza complications. J Epidemiol Community Health 2002; 56: 951-5.
11. Rochon PA, Gurwitz JH, Sykora K et al. Reader's guide to critical appraisal of cohort studies: 1. role and design. BMJ 2005; 330: 895-7.
12. Normand S-LT, Sykora K, Li P et al. Reader's guide to critical appraisal of cohort studies: 3. analytical strategies to reduce confounding. BMJ 2005; 330: 1021-3.
13. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-63.
14. Klungel OH, Martens EP, Psaty BM et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004; 57: 1223-31.
15. Concato J, Horwitz RI. Beyond randomised versus observational studies. Lancet 2004; 363: 1660-1.
16. Ahlberg A. Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965; 77 (Suppl.): 5-99.
17. Schimpf K, Fischer B, Rothmann P. Die ambulante dauerbehandlung der Hämophilie A. Dtsch Med Wochenschr 1976; 101: 141-8.
18. Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
19. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: A cost-effectiveness analysis. J Pediatr 1996; 129: 424-31.
20. Molho P, Rolland N, Lebrun T et al. Epidemiological survey of the orthopedic status of severe haemophilia A and B patients in France. Haemophilia 2000; 6: 23-32.
21. Fischer K, Astermark J, Van der Bom JG et al. Prophylactic treatment for severe haemophilia: Comparison of an intermediate dose regimen to a high dose regimen. Haemophilia 2002; 8: 753-60.
22. Fischer K, Van der Bom JG, Molho P et al. Prophylactic versus on demand strategies for severe haemophilia: A comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
23. Steen Carlsson K, Hojgard S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-66.
24. Erlemann R, Rosenthal H, Walthers EM, Almeida P, Calleja R. Reproducibility of the Pettersson scoring system - an interobserver study. Acta Radiol 1989; 30: 147-51.
25. Keller SD, Ware JE, Bentler PM et al. Use of structural equation modeling to test construct validity of the SF-36 health survey in ten countries: Results from the IQOLA project. J Clin Epidemiol 1998; 51: 1179-88.
26. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
27. Fischer K, Van der Bom JG, Mauser-Bunschoten EP et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7: 446-52.
28. Schramm W, Royal S, Kroner B et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
29. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
30. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004; 363: 1728-31.
31. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-92.
32. Ioannidis JPA, Haidich A-B, Pappa M et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286: 821-30.
33. Ioannidis JPA, Haidich A-B, Lau J. Any casualties in the clash of randomised and observational evidence? BMJ 2001; 322: 879-80.
34. Fischer K, Van den Berg HM. Prophylaxis for severe haemophilia: Clinical and economical issues. Haemophilia 2003; 9: 376-81.